PetVivo Holdings, Inc.
PETV Healthcare Medical Devices
PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025. In the quarter to June 2026, revenue grew 13.5%, EPS grew 44.4% and free cash flow grew 40.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow PETV
PetVivo Holdings, Inc. (PETV) EV/Sales
As of 16 October 2026, PetVivo Holdings, Inc. (PETV) trades at a EV/Sales of 23.4×. Over the past ten years it has ranged from 0.0× (December 2016) to 9,882× (January 2021); the current reading is higher than 40% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 18.3× | 73.97% |
| FY2025 | 10.5× | (26.60%) |
| FY2024 | 14.3× | (52.80%) |
| FY2023 | 30.4× | (70.21%) |
| FY2022 | 102× | (98.03%) |
| FY2021 | 5,182× | 787.74% |
| FY2020 | 584× | (91.14%) |
| FY2018 | 6,591× | 1,187.85% |
| FY2017 | 512× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 26.2× | 43.24% |
| Mar 2026 | 18.3× | (46.73%) |
| Dec 2025 | 34.4× | 64.64% |
| Sep 2025 | 20.9× | 70.57% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RBOT Vicarious Surgical Inc. compare | n/m |
| IRIX IRIDEX Corporation compare | 0.3× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| LFWD Lifeward Ltd. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. compare | 3.7× |
| ALUR Allurion Technologies, Inc. compare | 5.3× |
| PETV PetVivo Holdings, Inc. | 23.4× |
| HSCS HeartSciences Inc. compare | 556× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)